New hope for tough lymphoma: phase 3 trial pits SHR2554 against standard drug
NCT ID NCT06122389
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new drug called SHR2554 to an existing drug, chidamide, in 130 people with a rare type of lymphoma (PTCL) that has come back or not responded to at least one prior treatment. The main goal is to see if SHR2554 can delay cancer growth better than chidamide. Participants will receive either SHR2554 or chidamide, plus a dummy version of the other drug, so neither they nor their doctors know which they are getting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR2554 (a drug being tested) and chidamide (a standard drug)
- What this could lead to
- If SHR2554 works better than chidamide, it could offer a new treatment option for people with PTCL that has come back or not responded to prior therapy.
- What could go wrong
- This is a phase 3 trial, but it is still experimental. The new drug may not prove superior to the existing drug, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New cocktail therapy takes on tough lymphoma
- Promising lymphoma combo trial halted over safety issues
- New oral cancer drug enters first human safety trial
- New pill combo targets tough lymphoma
- New hope for rare blood cancer: phase 3 trial of XNW5004 launches
- New hope for Tough-to-Treat lymphoma: experimental drug shows promise